News
Market and company headlines
MCKAll
Loading
08:00-14:00Oct 232 Stories
2 cash-producing stocks to target this week and 1 we question
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
McKesson's Quarterly Earnings Preview: What You Need to Know
McKesson will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.
08:00-17:00Oct 213 Stories
McKesson (MCK) Stock Dips While Market Gains: Key Facts
The latest trading day saw McKesson (MCK) settling at $1, representing a -1.42% change from its previous close.
Is Trending Stock McKesson Corporation (MCK) a Buy Now?
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas, October 21, 2026--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 94 cents per share of common stock. The dividend will be payable on January 4, 2027, to shareholders of record on December 1, 2026.
17:00-23:00Oct 202 Stories
Would You Have Held McKesson Stock All The Way Up?
An investor who put $10,000 into McKesson Corporation (MCK) stock ten years ago would hold about $62,300 today, before dividends. That same money would have grown to about $35,900 in the S&P 500. Holding the drug distributor looks simple in hindsight, but it was not. So, how many times do you think the stock fell 20% or more along the way.
McKesson (MCK) Outperforms Broader Market: What You Need to Know
In the latest trading session, McKesson (MCK) closed at $1, marking a +1.95% move from the previous day.
04:00Oct 201 Story
09:00Oct 161 Story
17:00Oct 141 Story
11:00-22:00Oct 122 Stories
McKesson: Re-Rated Again Amidst Increased M&A Efforts
McKesson stock is up 170% since 2022. Learn whatâs driving growth, how recent M&A reshapes its portfolio, and if valuation limits upside.
McKesson (MCK) Stock Could Be 43% Undervalued Despite Its $1.4B Infusion Deal
McKesson has been a powerful long term winner. With the share price now at US$938.84, the real question is whether the business can keep generating cash flows that line up with that kind of run. With a Discounted Cash Flow (DCF) view available, the focus turns squarely to what the current price implies about the money the company can return to shareholders over time. Over the past 5 years the stock has delivered a very large 379.8% return, which puts a lot of past optimism about McKesson's...
09:00-11:00Oct 122 Stories
McKesson (MCK) Extends CVS Deal, Is The Stock Fully Valued?
McKesson (MCK) shares are in focus after the distributor reached an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, reinforcing a long-running customer relationship. McKesson’s share price has been trending higher, with a 30-day share price return of 6.5% and a 90-day move of 16.9%. The 1-year total shareholder return of 22.5% and 5-year total shareholder return of about 3.8x suggest that recent contract wins and distribution...
Does New CVS and EPIC Deals Reshape McKesson’s Pharmacy Distribution Narrative (MCK)?
In October 2026, EPIC Pharmacies introduced a new wholesale distribution model naming McKesson as one of two primary partners, while McKesson separately announced an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032 across mail order, specialty, retail pharmacies, and distribution centers. Together, these moves highlight McKesson’s entrenched role in both large national chains and independent pharmacies, reinforcing its position...
07:00-14:00Oct 92 Stories
McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?
McKesson Corporation (NYSE:MCK) is expanding its specialty healthcare operations through a $5.8 billion acquisition (including debt) of Option Care Health, Inc. (NASDAQ:OPCH), partnering with private equity firm Clayton, Dubilier & Rice to take the infusion-services provider private. Announced on October 6, the transaction values Option Care at $32.05 per share, representing a 37% premium to […]
If You Invested $1000 in McKesson a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
09:00Oct 81 Story
16:00-19:00Oct 52 Stories
OPCH Stock Soars 22% After-Hours On $5B McKesson Buyout Talks
Option Care is in advanced talks after a joint bid from McKesson and private equity firm Clayton Dubilier & Rice, FT reported.
Option Care Health surges 22% on report of $5 billion takeover by McKesson, CD&R
Investing.com -- Shares of Option Care Health (NASDAQ: OPCH) surged 22% in after-hours trading on Monday following a Financial Times report that healthcare giant McKesson and private equity firm Clayton Dubilier & Rice (CD&R) are in advanced talks to acquire the infusion services provider. The potential transaction is expected to value the company at more than $5 billion, including debt.
18:00-20:00Oct 12 Stories
Why McKesson Stock Soared More Than 5% Higher Today
The company extended its existing partnership with a major pharmacy chain.
Why McKesson (MCK) Stock Is Trading Up Today
Shares of healthcare distributor and services company McKesson (NYSE:MCK) jumped 4.4% in the afternoon session after the company reached an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032.
08:00-12:00Oct 12 Stories
McKesson extends CVS deal; shares rise
Investing.com -- McKesson Corporation (NYSE:MCK) shares rose 4.4% Thursday following the announcement of an extended pharmaceutical distribution agreement with CVS Health through June 2032.
McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
IRVING, Texas, October 01, 2026--McKesson Corporation (NYSE: MCK) announced today that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies, and distribution centers through June 2032.
07:00Oct 11 Story
13:00Sep 291 Story
14:00Sep 251 Story
08:00Sep 241 Story
09:00-19:00Sep 232 Stories
Why McKesson (MCK) Dipped More Than Broader Market Today
The latest trading day saw McKesson (MCK) settling at $880.5, representing a -1.2% change from its previous close.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
08:00Sep 231 Story
09:00Sep 221 Story
16:00Sep 211 Story
06:00-12:00Sep 172 Stories
Really like Northrop Grumman as a value play, says Regan Capital's Skyler Weinand
Skyler Weinand, Regan Capital CIO, joins 'Power Lunch' to discuss the best stocks for a sustained rate hike cycle.
1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
11:00-18:00Sep 162 Stories
McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
McKesson (MCK) closed at $887.29 in the latest trading session, marking a -1.36% move from the prior day.
Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong
Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]
05:00-13:00Sep 152 Stories
Here’s How Much You Would Have Made Owning McKesson Stock In The Last 5 Years
McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 23.05% on an annualized basis producing an average annual return of 34.83%. Currently, McKesson has a market capitalization of $104.88 billion.
Did McKesson’s (MCK) EPS Hike and Oncology Push Just Redefine Its Investment Narrative?
McKesson recently raised its full-year EPS guidance, projecting approximately 13%–15% growth (15%–17% excluding certain prior-year items), and outlined plans to rebrand its Medical-Surgical unit as Wellverse with a potential IPO targeted for the second half of 2027, alongside a pending acquisition of Precision Medicine Group to expand oncology and biopharma-services capabilities, subject to regulatory approval. This combination of upgraded earnings expectations, portfolio reshaping around...
11:00Sep 141 Story
02:00Sep 101 Story
08:00-10:00Sep 92 Stories
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Frazier Healthcare Partners Welcomes Tom Rodgers as Senior Partner
SEATTLE, September 09, 2026--Frazier Healthcare Partners, a private equity firm focused exclusively on the healthcare industry, is pleased to announce that Tom Rodgers will join the firm as a Senior Partner in October 2026. In this role, Mr. Rodgers will partner with Frazier’s Growth Buyout deal teams, providing strategic counsel on investment evaluation, portfolio value creation, and sector-level insights informed by more than 35 years of experience in healthcare strategy, corporate development
09:00-14:00Sep 83 Stories
3 Market-Beating Stocks for Long-Term Investors
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates
McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter. The company said Precision Medicine Group would expand two areas it has id
Reliant Infusion Names Tommy Pourmahram Chief Executive Officer
CHICAGO, September 08, 2026--Shore Capital Partners ("Shore" or "Shore Capital"), a Chicago-based private equity firm with an office in Nashville, today announced that Tommy Pourmahram has been named Chief Executive Officer of Reliant Infusion, a Shore portfolio company and provider of specialty infusion services.
06:00Sep 81 Story
22:00Sep 71 Story
17:00Sep 61 Story
16:00-22:00Aug 202 Stories
McKesson (MCK) Stock May Trade At A Discount As Cash Flow Holds Up
McKesson stock has delivered a very strong 336.0% return over the past five years, yet the current valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) model both still point to the shares trading below their estimated worth. Over 5 years, McKesson has returned 336.0%, which puts recent share price moves in the context of a long and very strong run. Expectations for McKesson's ability to keep converting revenue into reliable cash flows can support the...
McKesson (MCK) Joined A Tech Summit, Is It Still 13% Undervalued?
McKesson (MCK) is in focus after its technology leadership team joined the 17th Annual Atlanta C-Level Technology Leadership Summit, highlighting how its healthcare technology services fit alongside recent quarterly results and the current stock performance. See our latest analysis for McKesson. At a share price of $853.71, McKesson has eased slightly in the very short term, with a 1-day share price return that declined 1.79% and a 7-day share price return that declined 2.85%. However, its...
12:00-22:00Aug 192 Stories
RBC Capital Initiates Coverage of McKesson (MCK) with Sector Perform Recommendation
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.
09:00-11:00Aug 192 Stories
Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls
Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls
Winners And Losers Of Q2: McKesson (NYSE:MCK) Vs The Rest Of The Healthcare Providers & Services Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how healthcare providers & services stocks fared in Q2, starting with McKesson (NYSE:MCK).
05:00-07:00Aug 192 Stories
Barclays Maintains Overweight on McKesson, Raises Price Target to $1000
Barclays analyst Glen Santangelo maintains McKesson (NYSE:MCK) with a Overweight and raises the price target from $925 to $1000.
RBC Capital Initiates Coverage On McKesson with Sector Perform Rating, Announces Price Target of $845
RBC Capital analyst Ryan Halsted initiates coverage on McKesson (NYSE:MCK) with a Sector Perform rating and announces Price Target of $845.
13:00-17:00Aug 112 Stories
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.
Cardinal Health Q4 Earnings Call Highlights
Cardinal Health (NYSE:CAH) reported fourth-quarter fiscal 2026 results marked by growth in revenue, operating earnings and adjusted earnings per share, supported by demand in its pharmaceutical and specialty businesses and a one-time tariff-related benefit in its medical products segment. For the q